

Stephen John KENT
 "Immunomodulating Compositions, Uses Therefor and Processes for Their
 Production
 Attorney Docket No. 21415-0021-01.US

PCT/AU2004/000775

1/12




FIGURE 1

2/12




FIGURE 2

Stephen John KENT
 "Immunomodulating Compositions, Uses Therefor and Processes for Their
 Production
 Attorney Docket No. 21415-0021-01.US

PCT/AU2004/000775

3/12





FIGURE 3

4/12

E22 - control-immunised animal



H20 - 2xDNA/FPV-immunised animal




FIGURE 4

5/12




FIGURE 5

6/12




FIGURE 6

Stephen John KENT
 "Immunomodulating Compositions, Uses Therefor and Processes for Their
 Production
 Attorney Docket No. 21415-0021-01.US

PCT/AU2004/000775

7/12




FIGURE 7

Stephen John KENT
"Immunomodulating Compositions, Uses Therefor and Processes for Their
Production
Attorney Docket No. 21415-0021-01.US

PCT/AU2004/000775

8/12




FIGURE 8

Stephen John KENT
 "Immunomodulating Compositions, Uses Therefor and Processes for Their
 Production
 Attorney Docket No. 21415-0021-01.US

PCT/AU2004/000775

9/12




FIGURE 9

Stephen John KENT
"Immunomodulating Compositions, Uses Therefor and Processes for Their
Production
Attorney Docket No. 21415-0021-01.US

PCT/AU2004/000775

10/12




FIGURE 10

Stephen John KENT
"Immunomodulating Compositions, Uses Therefor and Processes for Their
Production
Attorney Docket No. 21415-0021-01.US

PCT/AU2004/000775

11/12




FIGURE 11

Stephen John KENT
 "Immunomodulating Compositions, Uses Therefor and Processes for Their
 Production
 Attorney Docket No. 21415-0021-01.US

PCT/AU2004/000775

12/12

RT (reverse transcriptase) enzyme of HIV-1

```

1 -----KVKQWPLTEEEKIKALVEICTEMEKEGKISKI 50
51 GPENPYNTPVFAIKKKDSTKWRKLVDFRELNRKRTQDFWEVQLGIPHPAGL 100
101 KKKKSVTVLDVGDAYFSVPLDKDFRKYTAFTIP SINNETPGIRYQYNVLP 150
151 QGWKGSPAIFQSSMTKILEPFRKQNPDIVIYQYMDLDLYVGSdleIGQHRT 200
201 KIEELRQHLLRWGFTTPDKKHQKEPPFLWMGYEL 234 [SEQ ID NO:2197]
```

17mer peptide

Known HIV-1 drug resistance site

ALVEICTELEKEGKISK	M41L	[SEQ ID NO:2198]
EICTEMEKGKISKIGP	E44D	[SEQ ID NO:2199]
NTPVFAIKRKDSTKWRK	K65R	[SEQ ID NO:2200]
PVFAIKKKNSTKWRKLV	D67N	[SEQ ID NO:2201]
FAIKKKDSKWRKLVDF	T69D	[SEQ ID NO:2202]
AIKKKDSTRWRKLVDFR	K70R	[SEQ ID NO:2203]
KDSTKWRKVVDRELNR	L74V	[SEQ ID NO:2204]
DSTKWRKLTDFRELNR	V75T	[SEQ ID NO:2205]
VQLGIPHPGGLKKKSV	A98G	[SEQ ID NO:2206]
PHPAGLKKNKSVTVLDV	K103N	[SEQ ID NO:2207]
DVGDAYFSIPLDKDFRK	V118I	[SEQ ID NO:2208]
RYQYNVLPMSGWGSPA	Q151M	[SEQ ID NO:2209]
KQNPDIVICQYMDLYV	Y181C	[SEQ ID NO:2210]
PDIVIYQYVDDLYVGS	M184V	[SEQ ID NO:2211]
PDIVIYQYIDDLVGS	M184I	[SEQ ID NO:2212]
IYQYMDLLVGSdleIG	Y188L	[SEQ ID NO:2213]
QYMDLYVASDLEIGQH	G190A	[SEQ ID NO:2214]
IEELRQHLLRWGFTTPD	L210W	[SEQ ID NO:2215] (also contains T215F as L210W follows 215 mutation)
QHLLRWGFTTPDKKHQK	T215F	[SEQ ID NO:2216]
QHLLRWGFTTPDKKHQK	T215Y	[SEQ ID NO:2217]
RWGFTTPDQKHQKEPPF	K219Q	[SEQ ID NO:2218]

Protease enzyme of HIV-1

```

1 PQITLWQRPLVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKMIGGI 50
51 GGFIVRQYDQILIEICGHKAIGTVLVGPTPVNIIGRNLLTQIGCTLN 99 [SEQ ID NO:2219]
```

17mer peptide

Known HIV-1 drug resistance site

QITLWQRPIVTIKIGGQ	L10I	[SEQ ID NO:2220]
TIKIGGQLREALDGTGA	K20R	[SEQ ID NO:2221]
ALLDTGADNTVLEEMNL	D30N	[SEQ ID NO:2222]
LPGRWKPKIIGGIGGFI	M46I	[SEQ ID NO:2223]
GRWKPKMIVGIGGFIKV	G48V	[SEQ ID NO:2224]
WKPKMIGGVGGFIKVRQ	I50V	[SEQ ID NO:2225]
KMIGGIGGLIKVRQYDQ	F53L	[SEQ ID NO:2226]
MIGGIGGFVKVRQYDQI	I54V	[SEQ ID NO:2227]
KVRQYDQIPIEICGHKA	L63P	[SEQ ID NO:2228]
TVLVGPTPANIIGRNLL	V82A	[SEQ ID NO:2229]
TVLVGPTPTNIIGRNLL	V82T	[SEQ ID NO:2230]
LVGPTPVNVIIGRNLLTQ	I84V	[SEQ ID NO:2231]
VNIIGRNLLTQIGCTLN	L90M	[SEQ ID NO:2232]

FIGURE 12